课题基金 / 基金详情

A basic trial of gene therapy against peritoneal dissemination of ovarian cancer by calponin h1 gene transfer

A basic trial of gene therapy against peritoneal dissemination of ovarian cancer by calponin h1 gene transfer
通过钙调蛋白 h1 基因转移对卵巢癌腹膜播散进行基因治疗的基本试验
批准号:
15591757
负责人:
KOBAYASHI Hiroaki
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

KOBAYASHI Hiroaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Calponin h1(CNh1), one of the actin-binding proteins, stabilizes the filaments of alpha-smooth muscle actin(α-SMA) and modulates cellular biological phenotypes. We have reported that the ovarian cancer cells probably make favorable environment for fheir intravasation through fhe down-regulation of CNh1 and α-SMA in the cells forming blood vessel walls. In this study, we investigated (1)the ovarian cancer-derived effects on peritoneal mesothelial cells and fibroblasfs, (2)the changes occurredin CNh1 gene-transfected cells, and (3)the efficacy of CNh1 gene therapy against the peritoneal dissemination of ovarian cancer.By adding the conditioned culture medium of human ovarian cancer cells, the reduction of both CNh1 andα-SMA expressions occurred in peritoneal cells and fibroblasts resulting in cellular retraction and suppression of actin stress fiber-formation. Especially in the monolayer of cultured peritoneal cells, intercellular dissociation was observed. The concentration of platelet- … More derived growth factor(PDGF) in an intratumoral fluid was significantly higher in ovarian cancers compared with that in benign ovarian tumors. Moreover, the ovarian cancer-derived inhibitory effect on α-SMA expression, which observed in cultured fibroblasts, was partially avoided by adding anti-PDGF neutralizing antibody into the conditioned medium of ovarian cancer cells. These observations opened up a possibility that ovarian cancer-derived secretor factors including PDGF made favorable environment for cancer invasion via down-regulated CNh1 and α-SMA in peritoneal cells and fibroblasts.Adenoviral vector-mediated CNh1 gene transfections into peritoneal cell lines and ovarian cancer cell lines induced the formation of longer and thicker actin steress fibers in each cell line, and the localization of fibers coincided with that of externally transducted CNh1 expression. Simultaneously, a monolayer of the infected peritoneal cells gained stability against the intercellular dissociation induced by the conditioned medium of ovarian cancer cells, and inhibited cancer cell invasion confirmed by cancer cell penetration through the peritoneal cell monolayer. On the other hand, CNh1-transfected ovarian cancer cells showed retarded growth property and invasiveness, the latter of which accompanied the impaired cell motility. When both the peritoneal cells and ovarian cancer cells were transfected at the same time, an additive inhibitory effect against the cancer cell invasion through the peritoneal cell monolayer was confirmed. By in vivo treatment experiments using nude mice, intraperitoneally injected CNh1-adenovirus successfully avoided ovarian cancer-induced change in peritoneal cell surface, and significantly prolonged the survival time of mice inoculated intraperitoneally with ovarian cancer cells.Consequently, CNh1 gene therapy against the peritoneal dissemination ot ovarian cancer is expected to be effective through the inhibitory effect in infected peritoneal cell layers against cancer invasion and the direct anti-tumor effect against cancer invasion and growth. The present therapy may be considered as a novel gene therapy based on the concept that the same gene plays bifunctional therapeutic roles against cancer : one is to repress cancer cells and the other is to reinforce host defense mechanism. Less
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
細胞間相互作用からみた卵巣癌腹膜播種の進展機序とその制御に関する研究
从细胞-细胞相互作用角度研究卵巢癌腹腔播散进展机制及其控制
DOI: --
发表时间: 2004
期刊: 日本産科婦人科学会雑誌 56
影响因子: --
作者: [H.Yahata, H.Kobayashi, et al., 小林 裕明]
通讯作者: 小林 裕明
Postoperative adjuvant with cisplatin, cyclophosphamide, and anthracycline(doxorubicin enirubicin nirarubicin) for endometrial cancer
子宫内膜癌术后辅助顺铂、环磷酰胺和蒽环类药物(阿霉素、恩柔比星、尼柔比星)
DOI: --
发表时间: 2004
期刊: International Journal of Clinical Oncology 9
影响因子: --
作者: [Yahata H, Kobayashi H et al.]
通讯作者: Kobayashi H et al.
In vivo-establishment and characterization of a paclitaxel- resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
紫杉醇抗性人卵巢癌细胞系的体内建立和表征仅在体内表现出增强的生长特性和耐药性。
DOI: --
发表时间: 2004
期刊: J Cancer Res Clin Oncol 130
影响因子: --
作者: [Ohishi Y, Ohishi Y, Ohishi Y, Okugawa K]
通讯作者: Okugawa K
DOI: --
发表时间: 2004
期刊: Acta Obst.Gvnaec.Jpn. 56
影响因子: --
作者: [Hamada, K., Kohno, S., Iwamoto, M., Yokota, H., Okada, M., Tagawa, M., Hirose, S., Yamasaki, K., Shirakata, Y., Hashimoto, K., Ito, M., H.Kobayashi]
通讯作者: H.Kobayashi
11
    Role of multifunctional matrix protein Thrombospondin-1 in periodontal disease
    • 批准号:
      16K11826
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2016
    • 负责人:
      KOBAYASHI Hiroaki
    • 依托单位:
    Development of education program tailored for junior and senior high school students who stutter base on their need and lifestyle
    • 批准号:
      24653291
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $1.91万
    • 财政年份:
      2012
    • 负责人:
      KOBAYASHI Hiroaki
    • 依托单位:
    Application-Aware Highly Hierarchical Memory Architecture
    • 批准号:
      24650018
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2012
    • 负责人:
      KOBAYASHI Hiroaki
    • 依托单位:
    Calponin h1-gene therapy using Tat-peptide vector against peritoneal dissemination of ovarian cancer
    国内基金
    海外基金
    机械力通过F-actin/YAP1-TEAD激活炎症通路调控角膜基质代谢的机制研究
    • 批准号:
      2026JJ60283
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      刘寒涵
    • 依托单位:
    CAR-T细胞F-actin逆流速率的动态光片解析和机制探索
    • 批准号:
      JCZRQNB202600313
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    Ezrin磷酸化抑制剂调控Ezrin/Actin- NRF2-HMOX1信号轴抑制铁死亡减轻脑缺 血再灌注损伤的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      郭允苗
    • 依托单位:
    基于组学技术探究梅毒免疫逃逸新机制:脂蛋白TpF1经TAGLN2调控PI3K/Akt通路下调F-actin聚合抑制巨噬细胞吞噬功能
    • 批准号:
      2025JJ90148
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      周湘萍
    • 依托单位: